SFCM
CMPX icon

Seven Fleet Capital Management’s Compass Therapeutics CMPX Stock Holding History

Seven Fleet Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.73M Sell
516,972
-51,775
-9% -$299K 0.86% 31
2025
Q4 		$3.05M Buy
+568,747
New +$2.63M 2.07% 7

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Seven Fleet Capital Management's CMPX Position: Q1 2026 in Review

Seven Fleet Capital Management reduced its Compass Therapeutics (CMPX) stake by 9.1% in Q1 2026, selling an estimated $299K and leaving 516,972 shares worth $2.73M. The position accounts for 0.86% of the portfolio, ranked #31.

Seven Fleet Capital Management first reported a position in CMPX in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.05M in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Seven Fleet Capital Management held 516,972 shares of Compass Therapeutics worth $2.73M as of Q1 2026.
  • Seven Fleet Capital Management sold 51,775 Compass Therapeutics shares in Q1 2026, an estimated $299K.
  • Compass Therapeutics made up 0.86% of Seven Fleet Capital Management's portfolio in Q1 2026, its #31 holding.
  • Seven Fleet Capital Management first reported a position in Compass Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Seven Fleet Capital Management's Compass Therapeutics position peaked at $3.05M in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.